Viemed Healthcare, Inc. (NASDAQ: VMD) demonstrated robust financial performance in fiscal year 2025, with net revenue increasing 21% year-over-year to $270.3 million, according to an updated coverage report from Stonegate Capital Partners. The company generated $14.9 million in net income and delivered record adjusted EBITDA of $61.4 million, highlighting its operational strength in the evolving healthcare landscape.
The growth was driven by continued platform momentum and contributions from the Lehan's acquisition, which has broadened Viemed's commercial exposure and diversified its payor mix. Additional tailwinds came from the broader healthcare industry shift toward in-home care and accelerating adoption of sleep and resupply services. Stonegate Capital Partners noted that sleep and resupply services are now overtaking ventilation in importance, improving the quality of Viemed's recurring revenue while reducing regulatory sensitivity.
A key challenge during the period was short-term friction from the updated National Coverage Determination (NCD), which added documentation requirements and tightened coverage criteria, temporarily moderating ventilator patient growth. However, the report emphasized that reimbursement levels remained unchanged and ventilator activity has already started to normalize. This regulatory adjustment represents a manageable hurdle rather than a fundamental threat to Viemed's business model.
Financial metrics further underscore the company's strong position, with free cash flow surging 141% year-over-year. Despite some margin mix pressure, Stonegate's analysis suggests that Viemed's fiscal year 2026 guidance and current valuation indicate durable growth remains underappreciated by the market. The Lehan's acquisition has created a longer runway for scaled growth by expanding Viemed's service offerings and market reach.
The broader implications of Viemed's performance extend beyond the company itself, reflecting significant trends in healthcare delivery. The accelerating shift toward in-home care represents a fundamental transformation in how medical services are provided, offering potential benefits including reduced healthcare costs, improved patient outcomes, and greater convenience for individuals requiring ongoing medical support. Viemed's success in navigating both growth opportunities and regulatory challenges provides insight into how healthcare companies can adapt to this changing environment while maintaining financial discipline.
For investors and industry observers, Viemed's performance offers a case study in healthcare sector adaptation. The company's ability to grow revenue substantially while managing regulatory changes demonstrates operational resilience. The transition toward sleep and resupply services, which now represent an increasingly important component of Viemed's business, reflects evolving patient needs and reimbursement patterns within the healthcare system. This evolution has implications for how healthcare providers structure their service offerings and manage regulatory risk exposure.
The full coverage report from Stonegate Capital Partners provides additional analysis and context regarding Viemed's market position and growth prospects. To view the full announcement, including downloadable images and additional information, visit https://www.stonegateinc.com.
